TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerGeoffrey R. Oxnard, Myung‐Ju Ahn, Kōichi Goto et al.|Annals of Oncology|2020Cited by 443
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLCShun Lu, Suresh S. Ramalingam, Terufumi Kato et al.|New England Journal of Medicine|2024Cited by 291
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D. Carvajal, Paul Nathan, Sophie Piperno‐Neumann et al.|Journal of Clinical Oncology|2018Cited by 274